Industry Newsgene therapyophthalmology4d molecular therapeuticsclinical trials
4D Molecular Therapeutics Completes Phase-3 Enrollment
6.1
4D Molecular Therapeutics announced on February 9 that it completed enrollment in 4FRONT-1, the Phase 3 trial of intravitreal 4D-150 for wet age-related macular degeneration. The randomized, double-masked study compares 4D-150 to aflibercept with a primary non-inferiority endpoint in mean change in best corrected visual acuity at 52 weeks. Barclays initiated Overweight coverage on January 27 with a $33 price target.
Key Points
- 1Announces completed enrollment for 4FRONT-1 Phase 3 trial of 4D-150 in wet AMD (Feb 9).
- 2Signals potential efficacy test via aflibercept-controlled non-inferiority endpoint in best corrected visual acuity at 52 weeks.
- 3Impacts investors: Barclays starts Overweight coverage with $33 target, potentially improving market visibility.
Scoring Rationale
Solid Phase-3 enrollment and Barclays coverage raise investor relevance, limited by company-specific scope and lack of AI/DS applicability.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
